Products

What will AGI do for Befunolol?

This classification denotes a beta-adrenergic blocking agent and anti-glaucoma agent with the molecular formula C16H21NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 418546MT3A, chemically known as ketone, 7-(2-hydroxy-3-(isopropylamino)propoxy)-2-benzofuranyl methyl but generally known as befunolol, which bears US NIH Compound Identifier 2309. Befunolol most often comes in base and hydrochloride forms. European Medicines Agency schedules Befunolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05682MIG. The term BEFUNOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules befunolol in its Anatomical Therapeutic Chemical (ATC) Classification. BEFUNOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule befunolol under HS 29329985 and SITC 51569. As of Q4 2014, BEFUNOLOL remains the US FDA Preferred Term for this commodity. Befunolol bears US NLM identifiers UMLS ID C0053071 and NCI Concept Code C73021. SMILES: O(CC(O)CNC(C)C)C1C2OC(CC2CCC1)C(=O)C.